Harold E. Selick
Independent ChairmanDr. Harold E. Selick, also known as Barry, Ph.D., serves as Chief Executive Officer of Hinge Bio, Inc. since January 2023. He serves as Director of Hinge Bio, Inc. He is a Member of the Business Advisory Board at Eleison Pharmaceuticals LLC. Dr. Selick serves as the Chairman of Protagonist Therapeutics, Inc. Dr. Selick serves as Chairman of Ethos Pharmaceuticals, Inc. He serves as the Chairman of Protagonist Pty Ltd. Dr. Selick served as the Chief Executive Officer of Threshold Pharmaceuticals, Inc. from June 2002 to March 31, 2017. Dr. Selick served as a Venture Partner at Sofinnova Ventures, Inc. from June 2002 until July 2007. He served as Venture Partner at Sofinnova Venture Partners VII, L.P. He co-founded Epiphany Biosciences, Inc. in 2001. Previously, he was the Co-Founder and President of Camitro Corporation since November 1999, served as the Chief Executive Officer from January 1999 to April 2002 and then Camitro U.K. Ltd. He served as the Vice President of Research at Affymax Research Institute from 1992 to 1999. Dr. Selick was a successful bench scientist and one of the earliest employees at Protein Design Labs, where he was a staff scientist and co-invented the technology underlying the creation of fully humanized mouse monoclonal antibodies and applied that to Zenapax, in partnership with Mr. Roche. He applied this technology to the creation of the Smart anti-TAC antibody. Dr. Selick served as the Head of Molecular Biology at Anergen, Inc. and held scientific positions with it. He served as the Executive Chairman of Threshold Pharmaceuticals Inc. since June 2002 until July 2007. He served as the Chairman of Catalyst Biosciences from 2006 to February 15, 2018. He served as Independent Chairman at Molecular Templates, Inc. He served as the Chairman of DiObex, Inc. He had been a Director and Lead Director of PDL BioPharma, Inc. since August 3, 2009 and December 2012 respectively Until December 2019 and served as its Chairman of the Board until December 2019. He has been an Independent Director of Protagonist Therapeutics, Inc. since February 2009. He serves as a Director of Bionaut Pharmaceuticals, Inc. He served as Director at Amunix Pharmaceuticals, Inc. He has been a Director of Molecular Templates, Inc. since August 2017. Dr. Selick joined the Molecular Templates, Inc. in August 2017. He was a Director of Catalyst Biosciences Inc. since 2003 until February 15, 2018. He has been a Venture Partner at Mission Bay Capital since 2018. He served as Director of Protein Mechanics, Inc. He served as a Director at Threshold Pharmaceuticals Inc. since June 2002. He served as a Director at InteKrin Therapeutics Inc. and Anergen Incorporated. He served as Director of ArQule Inc. He was a Damon Runyon-Walter Winchell Cancer Fund Fellow with Professor Bruce Alberts and an American Cancer Society Senior Fellow at the University of California, San Francisco. He is the co-author of 17 publications and co-inventor of 11 U.S. patents. Dr. Selick has served as Vice Chancellor of Business Development, Innovation and Partnerships at the University of California, San Francisco since April 2017. Dr. Selick holds a Ph.D. in Molecular Biology and Biology and a B.A. in Biophysics from the University of Pennsylvania in 1983.
Positions
- Company NameProtagonist Therapeutics, Inc.Stock CodePTGXPositionIndependent ChairmanColleagues
- DVDinesh V. PatelCEO, President, Secretary & Director
- AAAsif AliExecutive VP & CFO
- AMArturo M. MolinaChief Medical Officer
- VTVenkat ThalladiEVP & Chief Technical Officer
- NYNewman YeildingExecutive VP, Chief Scientific Officer
- CSChaitan S. KhoslaChairman of Scientific Advisory Board
- WDWilliam D. WaddillIndependent Director
- BGBryan GiraudoIndependent Director
